Akhmadeeva Gulnara Nailevna
Neurologist-Parkinsonologist, specialist in movement disorders, PhD in Medical Sciences
Education
- 2020 A Comprehensive Review of Movement Disorders for the Clinical Practitioner
- Virtual Aspen Course(International Parkinson and Movement Disorder Society)
- 2010 – 2020 Multiple advanced training cycles “Extrapyramidal Disorders. Clinic, Diagnosis, and Treatment” (KSMU, Kazan, RMANPO, Moscow) and “Cognitive Impairments and Dementia in Clinical Practice” (RMANPO, Moscow)
- 2017 Successful defense of a PhD dissertation in two specialties (neurology and genetics) on the topic “The Role of Monoamine Metabolism Genes in the Development of Parkinson’s Disease and Its Neuropsychological Manifestations” (NCN, Moscow), research supervisors — Prof. R.V. Magzhanov and Prof. I.M. Khidiyatova
- 2009 – 2013 Russian Academy of Sciences (Institute of Biochemistry and Genetics, Laboratory of Human Molecular Genetics), postgraduate studies
- 2008 – 2009 Bashkir State Medical University, internship, neurologist
- 2002 – 2008 Bashkir State Medical University, Faculty of Medicine (diploma with honors)
Work Experience
- 2021 – to the present Bashkir State Medical University, assistant of the Department of Neurology
- 2013 — 2020 Republican Center for Extrapyramidal Diseases and Botulinum Therapy LLC “NMH “MEDSTANDARD”
- 2011 – to the present time Republican Center for Extrapyramidal Pathology and Cognitive Disorders, RCH named after G.G. Kuvatov
- 2009 — 2011 City Clinical Hospital No. 21 (neurologist in the department for patients with acute cerebrovascular accident)
Clinical Research
- 2018 – 2021 Pharmacogenetic Study of Parkinson’s Disease: Search for Genetic Markers of Risk for Levodopa-Induced Dyskinesias
- 2017 — 2019 International genetic study of early and hereditary forms of Parkinson’s disease in collaboration with the Brain and Spine Institute (Paris, France)
- 2016 Clinical study of a new scale for assessing the severity of dyskinesias associated with Parkinson’s disease: Unified Dyskinesia Rating Scale UDysRS)
- 2012 – 2014 International Multicenter Clinical Study of the Medicinal Product Ropinirole for Medical Use PR ROP 111569 «Research using fixed doses of the drug and evaluating the dose-response relationship, studying ropinirole in extended-release form (ropinirole PR)» (IV фаза)
- 2012 Multicenter Study “Validation of the Unified Parkinson’s Disease Rating Scale of the International Movement Disorder Society” MDS-UPRDS)
- 2009 – 2013 Research on the Genetics of Susceptibility to Sporadic Parkinson’s Disease and Neuropsychological Disorders (Depression and Dementia)
Awards and Grants
RFBR Grant (2018) “Pharmacogenetic study of Parkinson’s disease: search for genetic markers of the risk of developing levodopa-induced dyskinesias”
Publications
1. The study of the role of genetic risk factors in levodopa-induced dyskinesia development in Russian patients with Parkinson’s disease: a pilot study / Akhmadeeva // Supplement: Abstracts of the MDS Virtual Congress 2020. Volume35, IssueS1. September 2020. Pages S1-S702. https://doi.org/10.1002/mds.28268.
2. The role of genetic factors in levodopa-induced dyskinesias development in russian patients with parkinson’s disease: a pilot study / Akhmadeeva // Journal of the neurological sciences. XXIV World Congress of Neurology, Dubai, October 26-31, 2019. https://doi.org/10.1016/j.jns.2019.10.289.
Projects
YouTube-channel for patients dedicated to Parkinson’s disease and cognitive impairments
- Free Marathon on Parkinson’s Disease for Patients and Their Relatives (2020) on an Online Platform Instagram
- Specialized information blog for patients with Parkinson’s disease and their relatives
- Mobile application for tracking well-being and medication management for patients with Parkinson’s Disease (2017)
